Dewan Nikhil, Ming Wendy, Holland Simon P, Yeung Sonia N, Iovieno Alfonso
Department of Ophthalmology and Visual Sciences, University of British Columbia, Vancouver, BC, Canada.
Cornea. 2019 Jul;38(7):914-917. doi: 10.1097/ICO.0000000000001968.
Acanthamoeba keratitis is a rare, vision-threatening disease. Commercially available antiamoebics are poorly cysticidal and highly toxic, and therapeutic keratoplasties can be complicated by recurrence or graft failure. We aimed to discuss the use of oral miltefosine for treatment of recalcitrant Acanthamoeba keratitis.
A 44-year-old contact lens wearer presented with a 2-week history of red painful eye and decreasing vision. After poorly responding to topical corticosteroid on the presumptive diagnosis of anterior uveitis, she developed radial keratoneuritis. Corneal scraping was positive for Acanthamoeba. No clinical response to treatment was observed with topical chlorhexidine 0.02%, polyhexamethylene biguanide 0.02%, and oral voriconazole. She then underwent 2 therapeutic keratoplasties with prompt recurrence of the disease in the keratoplasty graft.
Oral miltefosine was added to the treatment. She underwent a third penetrating keratoplasty 8 months later. The excised button was negative for amoeba. She continued miltefosine for 3 more months. No recurrence was observed after 30 months.
This case shows resolution of recalcitrant Acanthamoeba keratitis with oral miltefosine in an immunocompetent patient. Further clinical evidence would be needed to possibly incorporate this medication in the antiamoebic armamentarium.
棘阿米巴角膜炎是一种罕见的、威胁视力的疾病。市售的抗阿米巴药物杀包囊效果差且毒性高,治疗性角膜移植可能会因复发或移植失败而出现并发症。我们旨在探讨口服米替福新治疗难治性棘阿米巴角膜炎的应用。
一名44岁的隐形眼镜佩戴者出现眼红、眼痛2周,视力下降。在根据前葡萄膜炎的推测性诊断局部应用皮质类固醇治疗效果不佳后,她出现了放射状角膜神经炎。角膜刮片棘阿米巴检测呈阳性。局部应用0.02%洗必泰、0.02%聚六亚甲基双胍和口服伏立康唑治疗均未观察到临床反应。随后她接受了2次治疗性角膜移植,但角膜移植片疾病迅速复发。
治疗中加用了口服米替福新。8个月后她接受了第三次穿透性角膜移植。切除的植片阿米巴检测为阴性。她继续服用米替福新3个月。30个月后未观察到复发。
该病例显示口服米替福新可使一名免疫功能正常的患者难治性棘阿米巴角膜炎得到缓解。可能需要更多临床证据才能将这种药物纳入抗阿米巴药物库。